Patent · US Active

Hepatitis B virus (HBV) vaccines and uses thereof

US11021692B2 · kind B2 · utility

8Cited by

41References

27Claims

0Family size

Assignee

Janssen Sciences Ireland Unlimited Company · IE

Inventors

Daniel Boden · San Mateo, US
Helen Horton · Mol, BE
Jean-Marc Edmond Fernand Marie Neefs · Lier, BE
Soumitra Roy · Noordwijk, NL
Dorien De Pooter · Veerle, BE

Key dates

Filing date	Dec 18, 2018
Grant date	Jun 1, 2021
Priority date	—
Expiry date	Dec 18, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2730/10134
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Polynucleotides encoding hepatitis B virus (HBV) core antigen and polymerase antigen, and related combinations are described. Also described are vectors, such as DNA plasmids or viral vectors, expressing the HBV core and polymerase antigens, and immunogenic compositions containing the expression vectors. Methods of inducing an immune response against HBV or treating a HBV-induced disease, particularly in individuals having chronic HBV infection, using the immunogenic compositions are also described.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.